Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
14 01 2021
Historique:
pubmed: 5 1 2021
medline: 17 2 2021
entrez: 4 1 2021
Statut: ppublish

Résumé

Phenotypic screening of a Medicines for Malaria Venture compound library against

Identifiants

pubmed: 33395287
doi: 10.1021/acs.jmedchem.0c01727
pmc: PMC7816196
doi:

Substances chimiques

Antitubercular Agents 0
Bacterial Proteins 0
Membrane Transport Proteins 0
MmpL3 protein, Mycobacterium tuberculosis 0
Pyrazoles 0
Pyrimidinones 0
Iron E1UOL152H7

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

719-740

Subventions

Organisme : Wellcome Trust
ID : 203134/Z/16/Z
Pays : United Kingdom

Références

J Adv Pharm Technol Res. 2010 Apr;1(2):236-44
pubmed: 22247851
mBio. 2014 May 06;5(3):e01073-14
pubmed: 24803520
mBio. 2017 Aug 15;8(4):
pubmed: 28811344
Bioorg Med Chem. 2015 Nov 15;23(22):7240-50
pubmed: 26522089
J Med Chem. 2011 Jan 27;54(2):510-24
pubmed: 21186796
J Med Chem. 2012 Dec 27;55(24):10948-57
pubmed: 23240776
J Org Chem. 2001 Oct 19;66(21):7125-8
pubmed: 11597240
Nature. 1998 Jun 11;393(6685):537-44
pubmed: 9634230
J Pharmacol Toxicol Methods. 2017 Sep;87:108-126
pubmed: 28216264
Acta Biochim Pol. 1972;19(4):359-66
pubmed: 4664351
Antimicrob Agents Chemother. 2015 Apr;59(4):2256-64
pubmed: 25645825
Drug Saf. 1994 Oct;11(4):242-51
pubmed: 7848544
Mol Microbiol. 2003 Apr;48(1):77-84
pubmed: 12657046
J Org Chem. 2005 Nov 11;70(23):9644-7
pubmed: 16268652
Infect Immun. 2002 Jul;70(7):3371-81
pubmed: 12065475
J Biol Chem. 2004 Sep 17;279(38):40174-84
pubmed: 15247240
J Med Chem. 2015 Jan 22;58(2):753-66
pubmed: 25486447
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6748-6757
pubmed: 27572410
Medchemcomm. 2019 Jun 11;10(8):1342-1360
pubmed: 31534654
PLoS One. 2013 Apr 04;8(4):e60531
pubmed: 23593234
Acta Crystallogr Sect E Struct Rep Online. 2010 Feb 20;66(Pt 3):m319-20
pubmed: 21580258
Future Med Chem. 2013 Aug;5(12):1391-403
pubmed: 23919550
J Med Chem. 2007 Jan 11;50(1):101-12
pubmed: 17201414
Org Lett. 2006 Feb 2;8(3):395-8
pubmed: 16435843
PLoS One. 2013 Sep 23;8(9):e75245
pubmed: 24086479
J Bacteriol. 2009 Oct;191(20):6340-4
pubmed: 19684129
PLoS Pathog. 2011 Sep;7(9):e1002251
pubmed: 21980284
Bioorg Med Chem Lett. 2017 Jul 1;27(13):2974-2981
pubmed: 28512031
Cell. 2019 Jan 24;176(3):636-648.e13
pubmed: 30682372
mBio. 2017 Jan 17;8(1):
pubmed: 28096490
PLoS One. 2013 Oct 14;8(10):e78351
pubmed: 24155985
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28760899
Bioorg Med Chem Lett. 1999 Apr 5;9(7):1057-62
pubmed: 10230640
Chem Biol. 2015 Jan 22;22(1):63-75
pubmed: 25544046
J Med Chem. 2017 Dec 28;60(24):10118-10134
pubmed: 29148755
ACS Infect Dis. 2017 Jan 13;3(1):5-17
pubmed: 27726334
J Org Chem. 2017 Jun 2;82(11):5769-5781
pubmed: 28472882
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18792-7
pubmed: 19846780
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5051-6
pubmed: 21383189

Auteurs

Candice Soares de Melo (C)

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.

Vinayak Singh (V)

Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa.
South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.

Alissa Myrick (A)

Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa.

Sandile B Simelane (SB)

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.

Dale Taylor (D)

Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.

Christel Brunschwig (C)

Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.

Nina Lawrence (N)

Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.

Dirk Schnappinger (D)

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.

Curtis A Engelhart (CA)

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.

Anuradha Kumar (A)

Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.

Tanya Parish (T)

Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.

Qin Su (Q)

Genomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Timothy G Myers (TG)

Genomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Helena I M Boshoff (HIM)

Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Clifton E Barry (CE)

Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Frederick A Sirgel (FA)

South African Medical Research Council Centre for Tuberculosis Research/DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, Stellenbosch University, Tygerberg 7505, South Africa.

Paul D van Helden (PD)

South African Medical Research Council Centre for Tuberculosis Research/DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, Stellenbosch University, Tygerberg 7505, South Africa.

Kirsteen I Buchanan (KI)

Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Tracy Bayliss (T)

Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Simon R Green (SR)

Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Peter C Ray (PC)

Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Paul G Wyatt (PG)

Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

Gregory S Basarab (GS)

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Drug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.

Charles J Eyermann (CJ)

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.

Kelly Chibale (K)

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.

Sandeep R Ghorpade (SR)

Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH